AL Amyloidosis Clinical Trial

Study in Subjects With Light Chain (AL) Amyloidosis

Summary

The objective of this study is to evaluate the long-term safety and efficacy of NEOD001 in subjects with AL amyloidosis who have completed Study NEOD001-201.

View Full Description

Full Description

Global, multicenter, Phase 2b, open-label extension study of subjects with AL amyloidosis who had a hematologic response to first-line treatment for their amyloidosis (e.g., chemotherapy, autologous stem cell transplant [ASCT]) and completed Study NEOD001-201. Subjects in this study may receive concomitant chemotherapy. Subject screening will occur during the 28 days prior to the first administration of study drug, which may overlap with the last visit in Study NEOD001-201. If all eligibility requirements are met, the subject will be enrolled and Screening assessments will be completed. Study visits will occur every 28 days based on scheduling from Month 1 Day 1. A ±5-day window is allowed for visits starting after Month 1. Subjects who discontinue study drug before the End of Study Visit (EOS) should have an Early Treatment Discontinuation Visit 30 (±5) days after their final administration of study drug. Each subject's study participation may be up to 38 months or until the study is terminated, whichever occurs first. The study consists of a Screening Phase (1 month), Treatment Phase (36 months), and EOS Visit (30 [±5] days after the last dose).

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Completed the End of Study Visit in Study NEOD001-201

Adequate bone marrow reserve, hepatic and renal function, as demonstrated by:

Absolute neutrophil count (ANC) ≥1.0 × 109/L
Platelet count ≥75 × 109/L
Hemoglobin ≥9 g/dL
Total bilirubin ≤2 × upper limit of normal (ULN)
Aspartate aminotransferase (AST) ≤3 × ULN
Alanine aminotransferase (ALT) ≤3 × ULN
Alkaline phosphatase (ALP) ≤5 × ULN (except for subjects with hepatomegaly and isozymes specific to liver, rather than bone)
Estimated glomerular filtration rate (eGFR) ≥25 mL/min/1.73 m2 as estimated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, or measured GFR ≥25 mL/min/1.73 m2
Systolic blood pressure 80-180 mmHg
Women of childbearing potential must have a negative pregnancy test during Screening and must agree to use highly effective physician-approved contraception from Screening to 90 days following the last study drug administration
Male subjects must be surgically sterile or must agree to use highly effective physician-approved contraception from Screening to 90 days following the last study drug administration
Ability to understand and willingness to sign an informed consent form prior to initiation of any study procedures

Exclusion Criteria:

Any new medical contraindication or clinically significant abnormality on physical, neurological, laboratory, vital signs, or electrocardiographic (ECG) examination (e.g., atrial fibrillation; with the exception of subjects for whom the ventricular rate is controlled) that precludes continuation or initiation of treatment with NEOD001 or participation in the study
Symptomatic orthostatic hypotension that in the medical judgment of the Investigator would interfere with subject's ability to safely receive treatment or complete study assessments
Myocardial infarction, uncontrolled angina, uncontrolled ventricular arrhythmias, or ECG evidence of acute ischemia, within 6 months prior to the Month 1-Day 1 Visit
Severe valvular stenosis (e.g., aortic or mitral stenosis with a valve area <1.0 cm2) or severe congenital heart disease

ECG evidence of acute ischemia or active conduction system abnormalities with the exception of any of the following:

First degree atrioventricular (AV) block
Second degree AV block Type 1 (Mobitz Type 1/ Wenckebach type)
Right or left bundle branch block
Atrial fibrillation with a controlled ventricular rate (uncontrolled [i.e., >110 bpm] ventricular rate is not allowed [determined by an average of three beats in Lead II or 3 representative beats if Lead II is not representative of the overall ECG])
Has not recovered (i.e., equivalent to a Common Terminology Criteria for Adverse Events [CTCAE] ≥Grade 2) from the clinically significant toxic effects of prior anticancer therapy. Exception: subjects who have received treatment with a proteasome inhibitor such as bortezomib may have CTCAE Grade 2 neuropathy.

Received any of the following within the specified time frame prior to the Month 1-Day 1 Visit:

Oral or IV antibiotics, antifungals, or antivirals within 1 week, with the exception of prophylactic oral agents. Note: In the event that a subject requires the chronic use of antivirals, Medical Monitor permission is required for entry into the study.
Hematopoietic growth factors, transfusions of blood or blood products within 1 week
Chemotherapy, radiotherapy, HDAC inhibitors, or other plasma cell directed therapy within 2 weeks
ASCT within 4 weeks (i.e., ASCT is allowed if it occurred before enrollment in Study NEOD001-201 or after completion of Study NEOD001-201 if it was at least 4 weeks before Month 1-Day 1 of this study)
Major surgery within 4 weeks (or within 2 weeks following consultation with and approval of Medical Monitor)
Planned organ transplant during the study
Any investigational agent, other than NEOD001, within 4 weeks
Any experimental imaging agent directed at amyloid within 2 weeks

Active malignancy with the exception of any of the following:

Adequately treated basal cell carcinoma, squamous cell carcinoma, or in situ cervical cancer
Adequately treated Stage I cancer from which the subject is currently in remission and has been in remission for ≥2 years
Low-risk prostate cancer with Gleason score <7 and prostate-specific antigen <10 mg/mL
Any other cancer from which the subject has been disease-free for ≥2 years
History of Grade ≥3 infusion-related adverse events (AEs) or hypersensitivity to NEOD001
History of severe allergy to any of the components of NEOD001 such as histidine/L-Histidine, Trehalose, or Polysorbate 20
Currently known uncontrolled bacterial, viral, fungal, HIV, hepatitis B, or hepatitis C infection
Women who are breastfeeding
Any condition which could interfere with, or the treatment for which might interfere with, the conduct of the study or which would, in the opinion of the Investigator, unacceptably increase the subject's risk by participating in the study
Unable or unwilling to adhere to the study-specified procedures and restrictions
Subject is under legal custodianship

Study is for people with:

AL Amyloidosis

Phase:

Phase 2

Estimated Enrollment:

80

Study ID:

NCT03154047

Recruitment Status:

Terminated

Sponsor:

Prothena Biosciences Ltd.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 32 Locations for this study

See Locations Near You

City of Hope
Duarte California, 91010, United States
Colorado Blood Cancer Institute
Denver Colorado, 80218, United States
Mayo Clinic Hospital - Florida
Jacksonville Florida, 32224, United States
University of Chicago Medicine
Chicago Illinois, 60637, United States
Indiana University Simon Cancer Center
Indianapolis Indiana, 46202, United States
Tufts Medical Center
Boston Massachusetts, 02111, United States
Karmanos Cancer Institute
Detroit Michigan, 48201, United States
Mayo Clinic - Minnesota
Rochester Minnesota, 48201, United States
Memorial Sloan-Kettering Cancer Center
New York New York, 10065, United States
Duke University Medical Center
Durham North Carolina, 27705, United States
Cleveland Clinic
Cleveland Ohio, 44195, United States
Oregon Health & Science University
Portland Oregon, 97239, United States
Hospital of the University of Pennsylvania
Philadelphia Pennsylvania, 19104, United States
Vanderbilt University Medical Center
Nashville Tennessee, 37232, United States
The University of Texas MD Anderson Cancer Center
Houston Texas, 77030, United States
Medical College of Wisconsin
Milwaukee Wisconsin, 53226, United States
Westmead Hospital
Sydney New South Wales, 2145, Australia
Princess Alexandra Hospital
Woolloongabba Queensland, 4102, Australia
Eastern Health (Box Hill Hospital)
Box Hill Victoria, 3128, Australia
Medizinische Universität Wien
Vienna , 1090, Austria
Hôpital Dupuytren - CHU Limoges
Limoges , 87042, France
Hôpital Pitié-Salpêtrière
Paris , 75651, France
Charité - Universitätsmedizin Berlin
Berlin , 12200, Germany
University of Duisburg-Essen
Essen , 45122, Germany
Universitätsklinikum Hamburg-Eppendorf (UKE)
Hamburg , 20246, Germany
Universitätsklinikum Heidelberg
Heidelberg , 69120, Germany
Alexandra General Hospital of Athens
Athens , 11528, Greece
University Hospital of Patras
Patras , , Greece
Hadassah Medical Center (HMC)
Jerusalem , 91120, Israel
Fondazione IRCCS Policlinico San Matteo
Pavia , 27100, Italy
Hospital Clínic de Barcelona
Barcelona , 08036, Spain
Hospital Universitario Puerta de Hierro - Majadahonda
Majadahonda , 28222, Spain
Queen Elizabeth Hospital
Birmingham England, B15 2, United Kingdom
The Royal Free Hospital
London England, NW3 2, United Kingdom

How clear is this clinincal trial information?

Study is for people with:

AL Amyloidosis

Phase:

Phase 2

Estimated Enrollment:

80

Study ID:

NCT03154047

Recruitment Status:

Terminated

Sponsor:


Prothena Biosciences Ltd.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider